European Biopharmaceutical Enterprises

What European Biopharmaceutical Enterprises does

European Biopharmaceutical Enterprises (EBE) is a Brussels-headquartered, non-profit trade association founded in 2000 that operates as a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA). It represents approximately 50 biopharmaceutical companies — predominantly small and medium-sized enterprises — that use biotechnology to discover, develop, manufacture, and market new medicinal products in Europe. EBE does not produce commercial products or technology platforms; its core outputs are regulatory advocacy, policy position papers, working-group coordination, and convening platforms for industry-regulator dialogue.

EBE pursues its mission through five active working groups covering Advanced Therapy Medicinal Products (ATMPs), Personalised Medicine, Biotherapeutics/Biosimilars, Biomanufacturing, and Innovation & Funding. Its flagship programmatic asset is an annual regulatory conference on ATMPs co-organised with the European Medicines Agency since 2011, complemented by EMA-EBE regulatory policy summits, joint workshops with EuropaBio and ICPerMed, and contributions to the IMI public-private partnership and the Escher research project (with Lygature and Utrecht University). Distribution channels include a WordPress website, podcasts, webinars, Twitter, LinkedIn, YouTube, and in-person events.

EBE's revenue model is membership-based: companies using biotechnology to develop new medicinal products can apply for full or affiliate membership, contactable through Executive Director Barbara Freischem. Specific membership fees, sponsorship revenue, and EFPIA cost-sharing arrangements are not publicly disclosed. The organisation operates with 1-10 employees and is led by a Board of Directors; recent leadership transitions include Roberto Gradnik (2016-2018 outgoing president) and Eduardo Bravo (incoming president, 2016-2018).

Name

European Biopharmaceutical Enterprises

Legal name

European Biopharmaceutical Enterprises

Website

https://ebe-biopharma.eu

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

EBE is a Brussels-headquartered, non-profit trade association founded in 2000 and operating as a specialised group of EFPIA. It represents ~50 mostly SME biopharmaceutical companies, providing regulatory advocacy, EMA dialogue, working groups, and policy publications on ATMPs, personalised medicine, and biotherapeutics.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Industry Trade Association

NAICS

Professional Organizations (813920)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Health, Pharmaceuticals & Medical Devices Regulatory Cooperation (BPADANAJ)

akta.pro secondary industry

Biologicals Regulatory, Testing & Quality Assurance Services (AFABAEAO)

Keywords

• Biopharmaceutical trade association
• Regulatory advocacy services
• Industry policy representation
• Advanced therapy medicinal products
• Biopharmaceutical working groups

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Distribution channels3 records

Marketing channels8 records

Core offering

European Biopharmaceutical Enterprises (EBE) is a European trade association representing biopharmaceutical companies of all sizes, operating as a specialised group within EFPIA. EBE provides industry representation, regulatory advocacy with the European Medicines Agency (EMA) and EU authorities, working groups on advanced therapies, personalised medicine, biotherapeutics/biosimilars, biomanufacturing, and innovation funding, as well as conferences, position papers, and networking opportunities for member companies.

Product overview

European Biopharmaceutical Enterprises (EBE) is a trade association, not a product company. EBE represents biopharmaceutical companies of all sizes operating in Europe and is a specialised group within the European Federation of Pharmaceutical Industries and Associations (EFPIA). EBE advocates for its member companies in areas including Advanced Therapy Medicinal Products (ATMPs), biotherapeutics/biosimilars, personalised medicine, biomanufacturing, and innovation and funding models. EBE does not offer commercial products or services—it provides industry representation, regulatory advocacy, working groups, events, publications, and networking opportunities for its member biopharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• EBE Membership Program Membership program open to biopharmaceutical companies that use biotechnology to discover, develop and bring new medicinal products to market. Provides access to regulatory advocacy, working groups, policy engagement, networking, and industry representation in Europe. Full and affiliate membership tiers are available.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered major and core.

• LygaturemajorStrategic or Co-development Partner · 1 January 2017Partnership on the Escher project examining factors associated with successful ATMP development and commercialisation in Europe. EBE, EFPIA, and Utrecht University support this initiative.
• Utrecht UniversitymajorStrategic or Co-development Partner · 1 January 2017Partner in the Escher project with Lygature and EFPIA to examine ATMP development success factors.
• IMI (Innovative Medicines Initiative)coreStrategic or Co-development Partner · 1 January 2008World's largest public-private partnership in health with €2 billion initial budget (€1 billion from EU, €1 billion from pharmaceutical industry through EFPIA). EBE supports IMI projects and participates in discussions on ATMP development through IMI.
• EFPIA (European Federation of Pharmaceutical Industries and Associations)coreStrategic or Co-development PartnerEBE is a specialised group of EFPIA, representing the biopharmaceutical industry voice within the broader EFPIA structure. Joint working groups on Advanced Therapies and Personalised Medicine.
• Vaccines EuropecoreStrategic or Co-development PartnerPartnership within the EFPIA umbrella, representing vaccine manufacturers in Europe.
• EMA (European Medicines Agency)coreStrategic or Co-development PartnerAnnual regulatory conferences on ATMPs since 2011, regulatory policy summits, and ongoing dialogue on advanced therapy development and regulation.
• EuropaBiomajorStrategic or Co-development PartnerJoint workshops on biosimilar labelling and other shared policy topics in the European biotechnology space.
• ICPerMed (International Consortium for Personalised Medicine)majorStrategic or Co-development PartnerEBE-EFPIA report on benefits of personalised medicine discussed with ICPerMed representatives at working group meetings.

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• IFPMA (International Federation of Pharmaceutical Manufacturers & Associations): IFPMA is the global pharmaceutical industry federation. It is a broad incumbent peer operating one level above EBE/EFPIA on global health policy, WHO engagement and innovation funding advocacy.
• PhRMA (Pharmaceutical Research and Manufacturers of America): PhRMA is the US pharmaceutical research and biotechnology industry's leading trade association. It is a broad incumbent peer as the principal national biopharma advocacy body, sharing EBE's model of policy advocacy, working groups and regulator dialogue in a parallel jurisdiction.
• EFPIA (European Federation of Pharmaceutical Industries and Associations): EFPIA is EBE's parent federation and the broadest pharma industry association in Europe. Directly comparable as a membership-driven advocacy body representing the pharmaceutical industry to EU institutions, with EBE operating as a specialised biotech-focused sub-group within it.

Direct peers

• Vaccines Europe: Vaccines Europe is a specialised vaccine industry group within EFPIA. It is a direct peer as a sister specialised group under the EFPIA umbrella, focused on a distinct biopharmaceutical sub-sector and engaging with the same EU regulatory and policy stakeholders as EBE.
• EUCOPE (European Confederation of Pharmaceutical Entrepreneurs): EUCOPE represents small and mid-sized innovative pharmaceutical companies in Europe. It is a direct peer to EBE because both represent SME-heavy biopharma membership bases engaging EU regulators on ATMPs, market access and innovation funding.
• EuropaBio: EuropaBio is the European Association for Bioindustries, covering biotech across healthcare, industrial and agricultural applications. It is a direct peer as a Brussels-based biotech trade association partnering with EBE on biosimilar labelling workshops and broader EU biotech policy.
• Medicines for Europe: Medicines for Europe represents generic and biosimilar medicines manufacturers in Europe. It is a direct peer as a Brussels-based pharmaceutical trade association collaborating with EBE on biosimilars policy and co-signing joint Brexit policy documents.
• AESGP (Association of the European Self-Care Industry): AESGP represents European self-care and consumer health product manufacturers. It is a direct peer as another Brussels-based EFPIA-affiliated pharmaceutical association that co-signs joint life-science policy positions, including the Brexit paper alongside EBE.

Regional players

• BioIndustry Association (BIA): The BIA is the UK trade association for the bioindustry. It is a regional peer to EBE because it represents UK-based biotech SMEs with overlapping policy concerns, and is identified as a co-signatory on EBE's joint Brexit life-science policy paper.

Emerging players

• European Alliance for Personalised Medicine (EAPM): EAPM is a multi-stakeholder alliance driving personalised medicine policy in Europe. It is an emerging player peer because EBE/EFPIA actively engage with it — including joint EBE-EFPIA policy calls delivered at EAPM's 2017 Belfast congress — making it a comparable advocacy platform on a topic central to EBE's agenda.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ebe_eu
• YouTubeyoutube.com/channel/UCJ3GJ_qlQhkjLTZ3aR5kqZQ
• LinkedInlinkedin.com/company/1716979

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about European Biopharmaceutical Enterprises